Shares of Wellcome Plc &lt;WELL.L> fellsharply following a report that Bristol-Myers Co &lt;BMY> wouldseek U.S. Food and Drug Administration permission to test itsaids vaccine in humans by the end of March, dealers said.    Wellcome shares slumped to a quoted low of 453p on thereport after yesterday's 496p close but later rose to 464p.    Earlier this month a Wellcome spokesman said the companywas applying for licences in the U.S. And several majorcountries for its "Retrovir" drug which can be used for thetreatment of Aids. The U.K. Department of Health and SocialSecurity has already issued a marketing licence for "Retrovir." Reuter&#3;